Hologic price target lowered to $87 from $90 at Mizuho

Mizuho analyst Anthony Petrone lowered the firm’s price target on Hologic (HOLX) to $87 from $90 and keeps an Outperform rating on the shares. The company posted a mixed fiscal Q4, the analyst tells investors in a research note. The firm says the stock’s discounted valuation, strength in the core business, and lack of GLP-1 exposure keep it at Outperform.